Skip to content

Study · Randomized controlled trial · n = 216 · 2013

7 results

Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.

Davies M, Heller S, Sreenan S, Sapin H, Adetunji O, Tahbaz A, Vora J

Diabetes care28 Dec 2012Cited by 65 (Europe PMC)

PMID23275363 (opens in a new tab)PMCIDPMC3631870 (opens in a new tab)DOI10.2337/dc12-1333 (opens in a new tab)PepBankPUB-23275363
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, more exenatide recipients achieved A1C ≤7.0% and weight loss ≥1.0 kg than detemir recipients.

    In plain wordsIn patients with type 2 diabetes, exenatide improved combined glucose and weight target attainment more than detemir.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseA1C and weight composite target
    Study

    n = 216

    Comparator
    Insulin detemir
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    Target attainment
    44.1%
    exenatide
    Target attainment
    11.4%
    detemir

    Source sentences

    Summary
    Overall, 44.1% (95% CI, 34.7-53.9) of EQW-treated patients compared with 11.4% (6.0-19.1) of detemir-treated patients achieved the primary outcome (P < 0.0001).
    3 context sentences
    Summary · context
    The primary outcome was proportion of patients achieving A1C ≤7.0% and weight loss ≥1.0 kg at end point, analyzed by means of logistic regression.
    Summary · context
    This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas).
    Summary · context
    Patients were randomized to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma glucose ≤5.5 mmol/L) for 26 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, exenatide reduced A1C more than detemir.

    In plain wordsIn patients with type 2 diabetes, exenatide reduced A1C more than detemir.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseA1C reduction
    Study

    n = 216

    Comparator
    Insulin detemir
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    2 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    A1C change
    −1.3%
    exenatide
    A1C change
    −0.88%
    detemir

    Source sentences

    Summary
    Treatment with EQW resulted in significantly greater reductions than detemir in A1C (least-square mean ± SE, -1.30 ± 0.08% vs. -0.88 ± 0.08%; P < 0.0001) and weight (-2.7 ± 0.3 kg vs. +0.8 ± 0.4 kg; P < 0.0001).
    2 context sentences
    Summary · context
    This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas).
    Summary · context
    Patients were randomized to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma glucose ≤5.5 mmol/L) for 26 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, exenatide reduced weight more than detemir.

    In plain wordsIn patients with type 2 diabetes, exenatide reduced weight more than detemir.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight change
    Study

    n = 216

    Comparator
    Insulin detemir
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    Weight change
    −2.7 kg
    exenatide
    Weight change
    0.8 kg
    detemir

    Source sentences

    Summary
    Treatment with EQW resulted in significantly greater reductions than detemir in A1C (least-square mean ± SE, -1.30 ± 0.08% vs. -0.88 ± 0.08%; P < 0.0001) and weight (-2.7 ± 0.3 kg vs. +0.8 ± 0.4 kg; P < 0.0001).
    2 context sentences
    Summary · context
    This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas).
    Summary · context
    Patients were randomized to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma glucose ≤5.5 mmol/L) for 26 weeks.
  4. 04HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes, gastrointestinal adverse events occurred more frequently with exenatide than detemir.

    In plain wordsIn patients with type 2 diabetes, digestive adverse events were more frequent with exenatide than detemir.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n = 216

    Comparator
    Insulin detemir
    Analysis
    Secondary
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2 mg once weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal-related and injection site-related adverse events occurred more frequently with EQW than with detemir.
    2 context sentences
    Summary · context
    This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas).
    Summary · context
    Patients were randomized to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma glucose ≤5.5 mmol/L) for 26 weeks.
  5. 05HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes, injection site adverse events occurred more frequently with exenatide than detemir.

    In plain wordsIn patients with type 2 diabetes, injection site problems were more frequent with exenatide than detemir.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInjection site adverse events
    Study

    n = 216

    Comparator
    Insulin detemir
    Analysis
    Secondary
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    2 mg once weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal-related and injection site-related adverse events occurred more frequently with EQW than with detemir.
    2 context sentences
    Summary · context
    This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas).
    Summary · context
    Patients were randomized to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma glucose ≤5.5 mmol/L) for 26 weeks.
  6. 06HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes, neither exenatide nor detemir recipients experienced major hypoglycemia.

    In plain wordsIn patients with type 2 diabetes, neither exenatide nor detemir recipients had major low blood sugar events.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMajor hypoglycemia
    Study

    n = 216

    Comparator
    Insulin detemir
    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    2 mg once weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    There was no major hypoglycemia in either group.
    2 context sentences
    Summary · context
    This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas).
    Summary · context
    Patients were randomized to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma glucose ≤5.5 mmol/L) for 26 weeks.
  7. 07HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes, minor hypoglycemia affected five exenatide recipients and six detemir recipients.

    In plain wordsIn patients with type 2 diabetes, minor low blood sugar affected five exenatide recipients and six detemir recipients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedMinor hypoglycemia
    Study

    n: not reported in source

    Comparator
    Insulin detemir
    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    2 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    Minor hypoglycemia
    6%
    exenatide
    Minor hypoglycemia
    7%
    detemir

    Source sentences

    Summary
    Five (6%) patients in the EQW group and six (7%) patients in the detemir group experienced minor hypoglycemia; only one event occurred without concomitant sulfonylureas (detemir group).
    2 context sentences
    Summary · context
    This multicenter, open-label, parallel-arm study compared the efficacy and safety of exenatide once weekly (EQW) with titrated insulin detemir in patients with type 2 diabetes inadequately controlled with metformin (with or without sulfonylureas).
    Summary · context
    Patients were randomized to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma glucose ≤5.5 mmol/L) for 26 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.